Last reviewed · How we verify
Paxil-CR
Paxil-CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft.
Paxil-CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft. Used for Major depressive disorder, Generalized anxiety disorder, Panic disorder.
At a glance
| Generic name | Paxil-CR |
|---|---|
| Sponsor | University of Oklahoma |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Paxil-CR (paroxetine controlled-release) inhibits the reuptake of serotonin at presynaptic nerve terminals, leading to increased serotonin concentration in the synaptic space. This enhanced serotonergic neurotransmission is thought to improve mood and reduce anxiety symptoms. The controlled-release formulation provides steady drug levels throughout the day, improving tolerability compared to immediate-release formulations.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Panic disorder
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
- Social anxiety disorder
Common side effects
- Nausea
- Headache
- Somnolence
- Insomnia
- Sexual dysfunction
- Dizziness
- Sweating
Key clinical trials
- A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD (PHASE4)
- Management of Acute Tinnitus With Migraine Medications (PHASE4)
- Measurement-Based Care Vs. Standard Care for Major Depressive Disorder (NA)
- The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients (PHASE1, PHASE2)
- Lithium Versus Paroxetine in Major Depression (PHASE4)
- Paroxetine Hydrochloride 40 mg Tablets Under Fed Conditions (PHASE1)
- Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions (PHASE1)
- Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paxil-CR CI brief — competitive landscape report
- Paxil-CR updates RSS · CI watch RSS
- University of Oklahoma portfolio CI